SAB Biotherapeutics, Inc., (SABS) Social Stream



SAB Biotherapeutics, Inc., (SABS): $4.68

0.18 (+4.00%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add SABS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#93 of 393

in industry

SAB BIOTHERAPEUTICS INC (SABS) Price Targets From Analysts

Use the tables below to see what analysts covering SAB BIOTHERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-23 4 $23 $16.5 $18.625 $0.689 2603.19%
2021-12-02 4 $23 $16.5 $19.375 $0.689 2712.05%
2022-03-31 4 $23 $9 $16.375 $0.689 2276.63%
2022-04-04 4 $23 $9 $14.625 $0.689 2022.64%
2022-04-06 4 $23 $9 $14.1 $0.689 1946.44%
2022-05-15 4 $23 $7 $13.35 $0.689 1837.59%
2022-05-17 4 $23 $7 $12.85 $0.689 1765.02%
2022-08-11 4 $12.4 $3 $7.1 $0.689 930.48%
2022-08-23 3 $9 $3 $6.062 $0.689 779.83%
2022-11-16 2 $9 $3 $6.062 $0.689 779.83%
2022-11-21 2 $9 $3 $5.75 $0.689 734.54%
2023-01-18 3 $9 $3 $5.4 $0.689 683.74%
2023-04-18 3 $7 $3 $4.5 $0.689 553.12%
2023-05-17 3 $4 $3 $3.6 $0.689 422.5%
2023-05-26 3 $4 $2.6 $3.4 $0.689 393.47%
2023-08-22 3 $3 $2 $2.533 $0.689 267.63%
2023-10-06 3 $3 $2 $2.5 $0.689 262.84%
2023-11-15 3 $3 $1 $2 $0.689 190.28%

The Trend in the Analyst Price Target


Over the past 25 months, SABS's average price target has gone down $16.62.

SABS reports an average of 312.43% for its upside potential over the past 43 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-01-18 3 9 3 5.4 0.729 640.74%
2023-04-18 3 4 3 3.6 1.090 230.28%
2023-05-17 3 4 3 3.6 0.851 323.03%
2023-10-06 3 3 2 2.5 0.660 278.79%
2023-11-15 3 3 1 2.0 0.910 119.78%

SABS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.67 2 0 1 0 0 3

The Trend in the Broker Recommendations


SABS's average broker recommendation rating worsened by 0.67 over the prior 26 weeks.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In the context of all US stocks, SAB BIOTHERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 2004.84% of them.
  • SAB BIOTHERAPEUTICS INC's average analyst price target is greater than 184.36% of all US stocks.
  • SABS has a greater number of analysts covering the stock than 199.61% of all US stocks.
  • In terms of how SAB BIOTHERAPEUTICS INC fares relative to Healthcare stocks, note that its variance in analysts' estimates is lower than -1207.71% of that group.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to SAB BIOTHERAPEUTICS INC are MOLN, SOPH, and CDXC.

Make investment decisions regarding SABS using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!